![]() ![]() Some of the cookies are essential for parts of the site to operate and have already been set. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds.Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so.Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body.Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services. ![]() Obtains access to the information in a personal capacity.*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: Oliver Hughes/Rachel Farrington/Ollie HoareĪ copy of this announcement, together with other information about Halma, may be viewed on its website: I am a Private Investor There are no further details to be disclosed for Giles Kerr under Listing Rule 9.6.13R.Ĭlayton Hirst, Director of Corporate Affairs I would like to thank Roy for his valuable contribution to Halma, and particularly the support that he has given to me and the Board to ensure an orderly transition and onboarding of recent executive and non-executive Directors" His extensive executive and non-executive experience, particularly in the life sciences and technology sectors, will bring valuable insights and perspectives to the Board. "I am delighted that Giles is joining the Halma Board. Roy Twite, non-executive Director, who has served for nine years on the Board, will step down as a Director on 7 June 2024. Since 2007, Giles has held a number of non-executive director roles including Elan Corporation, Victrex plc, BTG plc, Oxford Sciences Innovation plc, Arix Bioscience plc and Senior plc. His executive career included senior financial roles at Arthur Andersen (leading to his appointment as National Partner), Amersham plc (latterly as Group Finance Director) and as Finance Director at Oxford University Innovation. He is currently Chair of PayPoint plc and was Senior Independent Director & Audit Committee Chair at Abcam plc, until it was acquired by Danaher in December 2023. Giles has a particularly strong background in driving strategic business growth as well as extensive M&A experience. Giles brings a wealth of experience gained across a variety of roles in life sciences, technology and industrial businesses. Giles will also be a member of Halma's Audit, Remuneration and Nomination Committees. Halma, the FTSE 100 global group of life-saving technology companies, today announces the appointment of Giles Kerr as an independent non-executive Director, with effect from 1 February 2024. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |